Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC
Clinical trial NCT07729670 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07729670
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2029-06-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.